The Sackler Family's $13 Billion Extraction: Profiting From America's Opioid Catastrophe
The Sackler family, owners of Purdue Pharma, systematically promoted OxyContin while concealing its addictive properties, contributing to an opioid epidemic that has killed over 500,000 Americans. Our investigation traces how the family extracted approximately $13 billion from Purdue Pharma through dividends and asset transfers even as the company faced mounting evidence that its marketing practices were fueling addiction and death. The Sacklers ultimately obtained legal protection from civil lawsuits through a controversial bankruptcy settlement that the Supreme Court initially rejected but was later renegotiated, shielding most of the family's fortune while providing a fraction of the estimated damages to victims. The case represents one of the most extreme examples of corporate impunity in American history.
The Marketing of Addiction
Purdue Pharma launched OxyContin in 1996 with a marketing campaign that fundamentally changed how opioids were prescribed in the United States. The company trained over 5,000 sales representatives to tell physicians that OxyContin's extended-release formulation made it less addictive than other opioids, a claim that had no scientific basis. Internal documents revealed in litigation show that Purdue knew its addiction claims were false as early as 1997, when the company received reports of OxyContin abuse and diversion. Rather than alerting regulators, Purdue intensified its marketing, targeting high-prescribing physicians, funding continuing medical education programs that promoted liberal opioid prescribing, and sponsoring pain advocacy organizations that pushed for expanded opioid use. Between 1996 and 2020, Purdue generated over $35 billion in OxyContin revenue. The company's marketing practices were so aggressive that internal documents described patients who reported addiction symptoms as pseudoaddicted, meaning they simply needed higher doses.
The Sackler Extraction Strategy
As litigation risks grew, the Sackler family implemented what court filings describe as an extraction strategy designed to move wealth from the company to family trusts and offshore accounts before creditors could access it. Between 2007 and 2018, the Sackler family withdrew approximately $13 billion from Purdue Pharma through dividends, asset transfers, and payments to family-controlled entities. Approximately $3.5 billion was transferred to offshore accounts and family trusts in jurisdictions including Switzerland, the Channel Islands, and the Cayman Islands. These transfers occurred while Purdue was aware of massive impending litigation and while the opioid crisis was killing tens of thousands of Americans annually. Former Purdue employees and financial advisors described the transfers as a deliberate effort to shield family wealth from legal liability, conducted with full knowledge that the company had caused catastrophic harm.
The Bankruptcy Shield
Purdue Pharma filed for bankruptcy in 2019, and the Sackler family sought to use the bankruptcy process to obtain releases from civil lawsuits without themselves filing for bankruptcy. Under the proposed plan, the Sacklers would contribute approximately $6 billion to a settlement fund in exchange for permanent legal immunity from all opioid-related civil claims. The Supreme Court ruled in June 2024 that non-debtor third-party releases were not authorized under current bankruptcy law, but Congress subsequently passed legislation specifically enabling such releases in mass tort cases, and a revised settlement was approved providing $6.5 billion from the Sacklers. Victims and their families have condemned the settlement as grossly inadequate, noting that the Sacklers retain an estimated $6-7 billion in personal wealth while victims receive payments averaging less than $5,000 per family. No Sackler family member has been criminally charged despite evidence that they personally directed the deceptive marketing practices that fueled the epidemic.
Key Findings
- The Sackler family extracted approximately $13 billion from Purdue Pharma while the opioid crisis they helped create killed over 500,000 Americans.
- Approximately $3.5 billion was transferred to offshore accounts and family trusts in anticipation of litigation.
- Purdue knew its claims about OxyContin's reduced addiction risk were false as early as 1997 but intensified marketing rather than alerting regulators.
- The Sacklers retained an estimated $6-7 billion in personal wealth while victims receive settlement payments averaging less than $5,000 per family.
Timeline
Purdue Pharma launches OxyContin with marketing claims about reduced addiction risk.
Purdue and three executives plead guilty to federal charges of misbranding OxyContin.
Purdue Pharma files for Chapter 11 bankruptcy amid thousands of opioid lawsuits.
Supreme Court rules against non-debtor releases in Purdue bankruptcy, later resolved through revised settlement.